Methods for treating cancer and predicting drug responsiveness in cancer patients

Featured are methods of treating a patient with cancer by administering, e.g., a secretory phospholipase A2 (sPLA2) hydrolysable, cisplatin-containing liposome composition (e.g., LiPlaCis). The patient may be assessed for their responsiveness to the liposomal therapy prior to treatment using the 0 m...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	MADSEN MOGENS WINKEL, BUHL ULLA HALD, RASMUSSEN ANNIE, JENSEN PETER BUHL, KNUDSEN STEEN
Format:	Patent
Sprache:	chi ; eng
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROCESSES OF PREPARING SUCH COMPOSITIONS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Featured are methods of treating a patient with cancer by administering, e.g., a secretory phospholipase A2 (sPLA2) hydrolysable, cisplatin-containing liposome composition (e.g., LiPlaCis). The patient may be assessed for their responsiveness to the liposomal therapy prior to treatment using the 0 methods, devices, and kits also described herein for detecting a level of one or more biomarkers in asample from the patient with cancer. 特征是通过施用例如分泌型磷脂酶A(sPLA)可水解的含顺铂的脂质体组合物(例如LiPlaCis)来治疗患有癌症的患者的方法。可评估患者在使用还如本文所述用于检测来自患有癌症的患者的样品中的一种或多种生物标记的水平的方法、装置和试剂盒进行治疗之前对脂质体疗法的响应性。